48,830
edits
Line 15: | Line 15: | ||
:Abbreviated ''PSAD''. | :Abbreviated ''PSAD''. | ||
Normal is often considered to be: <0.15 ng/ml. | |||
*Approximately 8% of individuals below the cut-point (0.15 ng/ml) have medium or high-grade cancer.<ref name=pmid12973074>{{Cite journal | last1 = Boulos | first1 = MT. | last2 = Rifkin | first2 = MD. | last3 = Ross | first3 = J. | title = Should prostate-specific antigen or prostate-specific antigen density be used as the determining factor when deciding which prostates should undergo biopsy during prostate ultrasound. | journal = Ultrasound Q | volume = 17 | issue = 3 | pages = 177-80 | month = Sep | year = 2001 | doi = | PMID = 12973074 }} | |||
</ref> | </ref> | ||
*In another series, 48% of individuals with cancer had a PSAD >0.15 ng/ml.<ref name=pmid22482342>{{Cite journal | last1 = Aganovic | first1 = D. | last2 = Prcic | first2 = A. | last3 = Kulovac | first3 = B. | last4 = Hadziosmanovic | first4 = O. | title = Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection. | journal = Med Arh | volume = 66 | issue = 1 | pages = 41-4 | month = | year = 2012 | doi = | PMID = 22482342 }} | |||
</ref> | </ref> | ||
*Difference between races have been noted; in those without prostate cancer:<ref name=pmid8998182/> | |||
**0.19 +/- 0.03 ng/ml (blacks). | |||
**0.11 +/- 0.01 ng/ml (whites). | |||
Better predictor than (unadjusted) serum PSA for: | Better predictor than (unadjusted) serum PSA for: |
edits